"Survivability Data Adds to Urgency to Make AMX0035 Available…"

Welcome to Connecting ALS. This week, Mike and Jeremy talk to Dr. Sabrina Paganoni, co-director of MGH Neurological Clinical Research Institute and principal investigator of the CENTAUR trial evaluating the effects of Amylyx Pharmaceutical’s AMX0035 on people living with ALS.

This week, Mike and Jeremy talk to Dr. Sabrina Paganoni, co-director of MGH Neurological Clinical Research Institute and principal investigator of the CENTAUR trial evaluating the effects of Amylyx Pharmaceutical’s AMX0035 on people living with ALS. Dr. Paganoni explains the results of that study, which were published in the October edition of Muscle and Nerve, and why the survivability data creates a new sense of hope in the search for treatments and a cure.

To read more about the results of the off-label extension study, go to https://www.als.org/stories-news/amx0035-survivability-data

To learn more about Dr. Paganoni’s research, check out https://www.massgeneral.org/doctors/19426/sabrina-paganoni

For a deeper dive into the survivability data, watch this webinar https://www.neals.org/for-people-with-als-caregivers/educational-webinars/long-term-survival-of-participants-in-the-centaur-trial

To keep the momentum going, sign and share the petition at als.org/petition

Find a transcript of this episode soon on Tumblr.

This episode was produced by Garrett Tiedemann and is brought to you by The ALS Association’s national office and the Association’s Minnesota/North Dakota/South Dakota Chapter
Brought to you by The ALS Association. © 2020 The ALS Association